Anya Biopharm (ROCO:7776) EBIT: NT$-62.81 Mil (TTM As of Dec. 2025)


ROCO:7776 Anya Biopharm Inc ROCO:7776
12 GF Score
Price NT$31.80
! 4 Warning Signs
View Full Analysis

What is Anya Biopharm EBIT?

Anya Biopharm ROCO:7776 12 EBIT is NT$-62.81 Mil as of Dec. 2025. GuruFocus rates ROCO:7776 with a GF Score™ of 12/100. The stock has 4 warning signs investors should review.

Anya Biopharm's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was NT$4.89 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-62.81 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Anya Biopharm's annualized ROC % for the quarter that ended in Dec. 2025 was -201.58%. Anya Biopharm's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 65.37%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Anya Biopharm's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -5.26%.

Anya Biopharm  (ROCO:7776) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Anya Biopharm's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-58.674 * ( 1 - 7.67% )/( (18.583 + 35.165)/ 2 )
=-54.1737042/26.874
=-201.58 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=411.355 - 9.678 - ( 387.066 - max(0, 10.011 - 393.105+387.066))
=18.583

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=413.871 - 7.934 - ( 370.772 - max(0, 8.189 - 392.695+370.772))
=35.165

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Anya Biopharm's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=9.778/( ( (9.025 + max(-5.971, 0)) + (8.735 + max(12.156, 0)) )/ 2 )
=9.778/( ( 9.025 + 20.891 )/ 2 )
=9.778/14.958
=65.37 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.119 + 0 + 3.823) - (9.678 + 0 + 0.235)
=-5.971

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(11.879 + 0 + 8.342) - (7.934 + 0 + 0.131)
=12.156

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Anya Biopharm's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-62.807/1193.633
=-5.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anya Biopharm EBIT Related Terms

Anya Biopharm EBIT Historical Data

* Premium members only.

The historical data trend for Anya Biopharm's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anya Biopharm EBIT Chart

Anya Biopharm Annual Data
Trend Dec22 Dec23 Dec24 Dec25
EBIT
-41.76 -28.03 -34.37 -62.81

Anya Biopharm Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial -14.74 -29.94 -4.44 -67.70 4.89

ROCO:7776 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Anya Biopharm's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anya Biopharm EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anya Biopharm's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Anya Biopharm's EV-to-EBIT falls into.


ROCO:7776
12GF Score
Anya Biopharm Inc ROCO:7776
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anya Biopharm EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-62.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$-62.81 Mil mean?
Anya Biopharm (ROCO:7776) has a EBIT of NT$-62.81 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Anya Biopharm.
Is Anya Biopharm's EBIT too high?
Anya Biopharm's current EBIT is NT$-62.81 Mil. Overall, Anya Biopharm has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Anya Biopharm's EBIT compare to VRTX and REGN?
Anya Biopharm's EBIT of NT$-62.81 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Anya Biopharm. Anya Biopharm's current EBIT is NT$-62.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anya Biopharm stock overvalued right now?
Anya Biopharm (ROCO:7776) has a current EBIT of NT$-62.81 Mil. The current EBIT is NT$-62.81 Mil. Anya Biopharm's overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Anya Biopharm (ROCO:7776), the current EBIT is NT$-62.81 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anya Biopharm Business Description

Address No. 3-2, Yuanqu Street, 4th Floor, Nangang, Taipei, TWN, 115603
Anya Biopharm Inc is a pharmaceutical company engaged in the Oral Delivery of Peptides. Its patented technology platform Mira/Je is a flexible solution easy to adapt to a large variety of peptides.
12GF Score

Get the complete analysis for ROCO:7776

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$31.80
Price